GlassScriptPhysician profile
Gregory A Cirotski
NPI 1750451118
$1,993.05
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $152 · 2021: $380 · 2022: $321 · 2023: $395 · 2024: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $313.47 | 2022-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $186.17 | 2021-2022 | |
| Glaxosmithkline, LLC. | $180.68 | 2023-2024 | Bexsero, Rotarix, Pediarix |
| Cranial Technologies, INC | $175.05 | 2019-2023 | Doc Band |
| Pfizer INC. | $144.46 | 2019-2024 | |
| Sanofi Pasteur INC. | $134.11 | 2019-2024 | |
| Adlon Therapeutics L.P. | $120.70 | 2020-2021 | |
| Corium, LLC | $116.71 | 2022-2024 | Azstarys |
| Neos Therapeutics, LP | $84.70 | 2019-2020 | |
| Tris Pharma INC | $82.59 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $56.12 | 2019-2022 | |
| Rhodes Pharmaceuticals L.P. | $52.96 | 2019 | |
| Merck Sharp & Dohme LLC | $51.34 | 2021-2022 | |
| Kaleo, INC. | $43.49 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $41.80 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $31.85 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $29.79 | 2024 | Flumist Quadrivalent |
| Shire North American Group INC | $26.99 | 2019 | |
| Kyowa Kirin, INC. | $25.99 | 2024 | Crysvita |
| Ucb, INC. | $25.60 | 2024 | Nayzilam |
| Noven Therapeutics, LLC | $19.42 | 2023 | Xelstrym |
| Seqirus USA INC | $18.63 | 2024 | Flucelvax |
| Teva Pharmaceuticals USA, INC. | $16.55 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cirotski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.